Project Grant R01CA296318
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $2.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
- The U.S. National Cancer Institute awarded a $855,249 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports DFCI's research to develop new approaches for targeting cell cycle proteins as potential cancer treatments. The key focus is on investigating how abnormal activation of cyclin-dependent kinases (CDKs) drives uncontrolled tumor cell proliferation, and exploring strategies to overcome limitations of...
- This federal Project Grant award of $163,500.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to develop new therapies for diffuse-type gastric cancer (DGAC). The primary awardee, The University of Texas MD Anderson Cancer Center, aims to unravel the mechanisms of DGAC tumorigenesis and apply that knowledge to lay a foundation for DGAC therapy development. Key objectives include determining the impact of drug candidates on DGAC stemness,...
- This $702,495 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope in California aims to develop innovative approaches for treating T-cell lymphomas (TCLs). The research will focus on targeting tumor-associated macrophages (TAMs) in the tumor microenvironment by inhibiting the CaMK2 kinase, which has been shown to play a pivotal role in TCL development. The research team will explore how...
- This federal Project Grant award of $109,076.00, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) on December 17, 2025, supports research to immuno-modulate diffuse midline glioma, an aggressive pediatric brain tumor, through epigenetic reprogramming. The project, led by the University of Miami, aims to advance scientific understanding and develop new treatment approaches for this deadly disease. The 4-year project period runs through September 1, 2029. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...
- The National Cancer Institute (NCI) awarded a $3,111,184 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports research to investigate the oncogenic mechanisms of the NPM1::TYK2 gene fusion and its role in driving the development of mature T-cell lymphomas, specifically anaplastic large cell lymphoma (ALCL). The project aims to advance the understanding of how this genetic alteration promotes lymphomagenesis...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...